Related Experiment Video
Updated: Mar 24, 2026

Surgical Angiogenesis in Porcine Tibial Allotransplantation: A New Large Animal Bone Vascularized Composite Allotransplantation Model
Published on: August 13, 2017
Voriconazole-induced periostitis: beyond post-transplant patients
Joshua D Reber1, Gavin A McKenzie2, Stephen M Broski2
1Department of Radiology, Mayo Clinic, 200 1st St. SW, Rochester, MN, 55905, USA. reber.joshua@mayo.edu.
Voriconazole-induced periostitis (VIP) can affect immunocompetent patients, not just transplant recipients. Early recognition of this rare condition by radiologists is key for timely diagnosis and treatment.
Area of Science:
- Pharmacology
- Radiology
- Rheumatology
Background:
- Voriconazole-induced periostitis (VIP) is a rare adverse effect of voriconazole, an antifungal medication.
- While often reported in transplant recipients on immunosuppressants, non-transplant patients are also at risk.
Observation:
- This case highlights VIP in an immunocompetent, non-transplant patient with a history of fungal infection in an abdominal aortic stent graft.
- The patient was on long-term suppressive voriconazole therapy.
Findings:
- Delayed diagnosis is common in non-transplant patients due to unfamiliarity with VIP outside of immunosuppressed populations.
- Radiologists play a crucial role in identifying periostitis on imaging and reviewing patient medication lists.
Implications:
- Prompt diagnosis of VIP can be facilitated by radiologist awareness and correlation with voriconazole use.
- Early identification and treatment can lead to symptom resolution and prevent further complications.
More Related Videos
Related Concept Videos
Kidney Transplant III: Nursing Management
Kidney Transplant I: Introduction
Antifungal Agents
Pericarditis IV: Nursing Management
Endocarditis IV: Nursing Management
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications

